Rezolute, INC 10-K annual reports

Rezolute, Inc. reported that its Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism did not meet its primary or key secondary endpoints, leading to ongoing discussions with the FDA regarding a potential regulatory path forward.

Rezolute, Inc. reports significant progress in its ersodetug clinical trials for hyperinsulinism, securing over $107 million in net proceeds from recent equity financings, despite ongoing net losses.

Rezolute, Inc.'s annual 10-K filing details the company's clinical advancements, financial status, and future plans, including progress in Phase 3 trials for its lead drug candidate.